Why is Glenmark Pharma falling/rising?

As of 25-Jul, Glenmark Pharmaceuticals Ltd. is currently priced at 2,140.00, reflecting a decrease of 4.0 points or 0.19%. The stock has underperformed its sector today, with a performance drop of 0.36%. Despite this short-term decline, Glenmark has shown strong performance over the past month, with a 25.00% increase, and impressive returns of 49.65% over the last year. However, there is a notable decline in investor participation, as evidenced by a 53.29% drop in delivery volume compared to the 5-day average. The company maintains a low Debt to EBITDA ratio of 1.00 times, indicating a strong ability to service debt, and has reported positive results for the last four consecutive quarters, with a significant growth in PAT. High institutional holdings at 38.3% suggest that informed investors are backing the stock, which has consistently outperformed the BSE500 over the last three years.
In the broader market context, Glenmark's short-term performance has been less favorable compared to the benchmark, as it has declined by 3.74% over the past week while the Sensex has only decreased by 0.36%. Despite this recent underperformance, Glenmark's year-to-date return of 33.01% significantly outpaces the Sensex's 4.25% gain, indicating a strong overall performance relative to the market. The stock's liquidity remains adequate for trading, which may help stabilize its price in the face of recent declines.